Summarized by Masters of Longevity from PR Newswire.
GlycoNex submitted a marketing application for SPD8 after positive Phase 3 results.
Key Takeaways
- Company submitted SPD8 marketing application to Japan's PMDA.
- Phase 3 found SPD8 equivalent on lumbar spine BMD at Month 12.
- Approval could come as early as the end of 2027.
